T he p53 checkpoint function represents one of the most relevant tumor suppressor mechanisms in humans. 1 In addition to its role in p53 checkpoint control, p53 influences cellular differentiation and stem cell function. p53 induces differentiation of embryonic stem cells, whereas loss of p53 can increase the formation of pluripotent stem cells. [2] [3] [4] [5] [6] In various somatic tissues, p53 restricts self-renewal of adult stem cells, including hematopoietic, neuronal, and breast epithelial stem cells. [7] [8] [9] In human cancer, p53 mutations are associated with poorly differentiated tumors, including hepatocellular carcinoma (HCC). 10, 11 Vice versa, the reintroduction of p53 has been shown to induce differentiation of tumor cells. 12 Dedifferentiation of p53-mutant tumors could point to a stem cell origin of the tumors. In agreement with this hypothesis, it has been shown that p53 restricts the aberrant self-renewal of stem and progenitor cells carrying oncogenic alterations, specifically that p53 deletion promotes self-renewal of myeloid progenitor cells expressing oncogenic Kras G12D . 13 Similarly, p53 deficiency cooperates with Pten inactivation to promote aberrant self-renewal of neural progenitor cells. 14 In these scenarios, increases in progenitor cell self-renewal resulted in higher frequencies of leukemia or glioblastoma formation. p53 deletion may also lead to transformation by inducing dedifferentiation and reprogramming of differentiated organ cells. 15 In addition to the possible impact of p53 on dedifferentiation and stem cell self-renewal, it remains an open question whether loss of p53 alone is sufficient to induce cancer in solid organs. Mutations in the p53 gene occur in approximately 20% of HCCs, but more than 50% of aflatoxin-induced HCCs show p53 mutations as an early molecular event. 16 -19 There is evidence that liver tumors with features of mixed differentiation occur in 20%-30% of patients 20 -22 and may show similarities to stem and progenitor cells in gene expression profiles. 11, 23, 24 These findings have fueled the discussion whether stem and progenitor cells could represent the cell type of origin of liver cancer formation.
Here we analyzed consequences of hepatic deletion of p53 in adult mouse liver. The study provides the first experimental evidence that p53 deletion as a single genetic lesion can lead to formation of liver tumors with bilineal differentiation and altered Rb checkpoint gene expression.
Materials and Methods

Mouse Models
Conditional Trp53 F2-10/F2-10 knockout mice 25 were crossed with AlfpCre transgenic mice. 26 The following experimental cohorts on the C57BL/6J background were generated: AlfpCre ϩ Trp53 ⌬2-10/⌬2-10 ϭ p53 Ϫ/Ϫ , AlfpCre ϩ Trp53 ⌬2-10/ϩ ϭ p53 ϩ/Ϫ , and AlfpCre Ϫ Trp53 F2-10/F2-10 ϭ p53 ϩ/ϩ . Additionally, we used Cdkn1a Ϫ/Ϫ mice (p21 Ϫ/Ϫ ). 27 NMRI nu/nu mice or NOD-scid IL2Rg null mice were used for transplantation assays. The animals were maintained in a specific pathogen-free environment and monitored weekly for tumor formation. Cells were subcutaneously injected with 25% Matrigel (BD Biosciences, San Jose, CA) into 4-to 6-week-old mice. All animal experiments were approved by the state government of Baden-Württemberg (protocol number 35/9185.81-3/940).
Isolation of Cells From Adult Mouse Liver
Cells were isolated from postnatal mouse livers by 2-step collagenase perfusion. Liver progenitor cells (LPCs) were isolated by fluorescence-activated cell sorting as described in Supplementary Materials and Methods. 28 Hepatocytes were purified by centrifugation in 50% Percoll (50g for 10 minutes).
In Vitro Colony-Forming Assay
LPCs were single cell sorted onto collagen type I-coated 96-well plates and cultured as described in Supplementary Materials and Methods. 28 Colony numbers were analyzed 3 weeks after initiating the cultures.
Genome-Wide Amplification
Genome-wide amplification of DNA was performed as described previously (see Supplementary Materials and Methods). 29, 30 
Array-Comparative Genomic Hybridization
Array-comparative genomic hybridization (aCGH) was performed using a genome-wide oligonucleotide microarray platform (mouse genome CGH 44K or 180K microarray kit; Agilent Technologies, Santa Clara, CA). As reference DNA, we used male DNA from the same mouse strain. Samples were labeled with the Agilent Genomic DNA Labeling Kit (Agilent Technologies) according to the manufacturer's instructions. Slides were scanned using a microarray scanner, and images were analyzed using DNA Analytics 4.0 (both from Agilent Technologies) with the statistical algorithm ADM-2.
Microarray Analysis
Gene expression analysis was performed using the Mouse GE 4x44Kv2 Microarray Kit (Agilent Technologies). Samples were labeled with the Quick Amp Labeling Kit (Agilent Technologies) according to the manufacturer's instructions. Slides were scanned using a microarray scanner (Agilent Technologies). All expression data were deposited in Gene Expression Omnibus (GEO accession number GSE34760).
Statistical Analysis
The 2 test, unpaired Student t test, and Fisher exact test were used for calculating statistical significance with GraphPad Prism (GraphPad Software, Inc, La Jolla, CA) and R version 2.14 (http://www.r-project.org).
Further experimental procedures are given in Supplementary Materials and Methods.
Results
Homozygous Deletion of p53 as a Single Genetic Lesion Induces Liver Cancer Exhibiting Mixed Lineage Differentiation and Chromosomal Instability
To evaluate the role of p53 deletion in liver carcinogenesis, Trp53 F2-10/F2-10 mice were crossed with transgenic mice expressing the Cre-recombinase under the liver-specific albumin/␣-fetoprotein enhancer promoter, which is activated on embryonic days 10 -11. 25, 26 Homozygous deletion of p53 in mouse liver (p53 Ϫ/Ϫ ) consistently led to tumor formation in 14-to 20-month-old mice ( Figure 1A) . Most of the mice developed liver cancer ( Figure 1B) . None of the p53 ϩ/Ϫ mice and p21 knockout mice developed liver cancer ( Figure 1A ), indicating that formation of liver cancer in response to p53 deletion involves p21-independent mechanisms.
In agreement with previous studies on carcinogen-induced liver cancer, 31 liver tumor formation was significantly accelerated in p53 Ϫ/Ϫ male compared with female mice (Supplementary Figure 1A) . Macroscopically, liver tumors in p53 Ϫ/Ϫ mice were typically whitish and sclerotic ( Figure 1C ). Histologic analysis revealed ductular (bile ducts) and trabecular structures (hepatocytic) as well as a high stromal content ( Figure 1D and E). Southern blot and quantitative reverse-transcription polymerase chain reaction analyses showed that these stromal cells were nontransformed, p53 wild-type cells ( Supplementary Figure 1B-E). The p53 Ϫ/Ϫ livers did not exhibit premalignant lesions (eg, basophilic or clear cell foci) that are typically found in carcinogen-treated mouse liver. 32 The earliest detectable, focal lesions in p53 Ϫ/Ϫ mouse livers were microscopically indistinguishable from advanced hepatocellular carcinoma/cholangiocellular carcinoma (HCC/CC) of older mice ( Figure 1E ). p53 Ϫ/Ϫ liver tumors expressed markers of cholangiocytic (K19-positive) and hepatocytic (albumin-positive) differentiation ( Figure 1F ) as well as the A6 epitope ( Figure 1F ), an uncharacterized epitope expressed by oval cells. 33, 34 Expression of ␣-fetoprotein was not detected (data not shown).
aCGH of DNA from whole tumor biopsy specimens revealed genomic imbalances. Loss of chromosomes 9 and 12 as well as gain of chromosome 15 were observed at a high frequency (Supplementary Figure 1F and Supplementary Table 1 ).
aCGH analysis of microscopic tumors indicated that these early tumors contain some chromosomal lesions (loss of chromosome 12, gain of chromosome 15) that are also present with high frequency in macroscopic tumors (Supplementary Table 1 ). These results support the histologic observation that microscopic tumors were similar to advanced tumors in p53 Ϫ/Ϫ liver. Nontransformed p53 Ϫ/Ϫ liver did not show evidence for clonal chromo- Figure 1F) . Chromosomal aberrations in chemically (diethylnitrosamine [DEN])-induced HCC in p53 ϩ/ϩ mice were distinct from those in spontaneous liver cancers in p53 Ϫ/Ϫ mice (Supplementary Table 1 and Supplementary Results).
Tumorigenicity of p53-Deficient Liver Carcinoma Does Not Depend on a Subpopulation of Tumor-Maintaining Cells
Recent studies revealed experimental evidence that the tumorigenicity of some tumors depends on a subpopulation of tumor cells. 35, 36 Quantitative real-time polymerase chain reaction and immunofluorescence staining revealed an increased expression of tumor stem cell markers in p53 Ϫ/Ϫ liver tumors compared with the surrounding, nontransformed liver (Supplementary Figure 2A- 
C).
To functionally test the possible existence of a tumormaintaining cellular subpopulation in p53 Ϫ/Ϫ liver carcinomas, freshly established cell cultures from liver tumors were purified using cancer stem cell surface markers as well as a functional marker (side population) ( Table 1) . Limiting dilution transplantation of cancer cell cultures into immunocompromised mice revealed a high tumorforming capacity of p53 Ϫ/Ϫ liver carcinoma cells (1 of 15 cells formed tumors) independent of the tested marker ( Table 1 ), indicating that these carcinomas did not depend on a subfraction of tumor-maintaining cells.
p53 Deletion Enhances Colony-Forming Capacity of Bipotent LPCs During Aging
The development of bilineal cancers in p53 Ϫ/Ϫ livers suggested that tumors may be derived from LPCs. Using recently established protocols, 28 progenitor cells were purified from livers of 2-to 3-and 8-to 10-monthold mice ( Figure 2A ) and sorted as single cells into 96-well plates. In agreement with previous publications, 28 a subset of these purified single cells exhibited clonal expansion capacity ( Figure 2B and C). Most of the colonies expressed only cholangiocytic marker (K19; Figure 2B ), but some colonies showed a higher proliferation capacity and a mixed lineage differentiation into albumin and K19-expressing cells ( Figure 2C ). A small subset of cells exhibited coexpression of both markers.
Eight percent to 12% of the freshly purified LPCs had the capacity to form cholangiocytic colonies in cell culture (Figure 2D ) with no significant effect of age or p53 genotype. A total of 0.55%-0.82% of the purified LPCs from 2-to 3-month-old mice exhibited bilineal differentiation capacity, which was not affected by p53 gene status ( Figure 2E ). p53-positive mice exhibited a strong age-dependent decline in LPCs to form bilineal colonies (only 0.045% of the sorted cells formed colonies with bilineal differentiation in 8-to 10-month-old mice; Figure 2E ). In contrast, isolated LPCs from p53 Ϫ/Ϫ mice did not show a significant age-dependent decline in the capacity to form bilineal colonies ( Figure 2E ). Previous studies have shown that cells from these bilineal colonies can self-renew and exhibit bilineal colony-forming capacity at the single-cell level at later passage. 28 p21, a downstream target of p53, can affect stem cell self-renewal. 37 ,38 Therefore, we analyzed LPCs from 8-to 10-month-old p21 Ϫ/Ϫ mice. Deletion of p21 was associated with a significant increase in colonies with bilineal differentiation (0.22% of sorted cells) compared with agematched p53-positive mice ( Figure 2E ), but the number of bipotent progenitor cells remained reduced compared with age-matched p53 Ϫ/Ϫ mice. Together, these data indicated that p53 induces age-dependent restrictions in bilineal colony-forming capacity of LPCs involving p21-dependent and p21-independent mechanisms.
p53 Deletion Increases Clonogenic Capacity and Chromosomal Instability of LPCs and Differentiated Hepatocytes
p53 deletion also enhanced the capacity of bilineal and cholangiocytic colonies (derived from single sorted cells) to form cell lines (Supplementary Figure 3A) . In vivo bromodeoxyuridine incorporation in LPCs did not reveal a significant difference in p53 Ϫ/Ϫ mice compared with p53-positive mice (Supplementary Figure 3B) . However, the analysis could not exclude differences in the rate of proliferation in bipotent LPCs because the fraction of bipotent cells was less than 1% in this subpopulation of LPCs (see Figure 2) .
To analyze the influence of p53 gene status on growth of differentiated liver cells, freshly isolated hepatocytes were cultivated. Hepatocytes isolated from 8-month-old p53 Ϫ/Ϫ mice were able to grow in vitro, whereas hepatocytes isolated from p53 ϩ/Ϫ , p53 ϩ/ϩ , and p21 Ϫ/Ϫ mouse liver failed to proliferate and exhibited increased rates of cell death from day 14 after initiation of cultures, leading to complete loss of the cultures after 1-2 months (Supplementary Figure 4A and B). Primary hepatocyte cultures from p53 Ϫ/Ϫ liver showed a change in morphology over time, indicating that hepatocytes dedifferentiated and acquired mixed differentiation over time (Supplementary NOTE. Primary tumor cells were expanded from p53 Ϫ/Ϫ liver tumors and fluorescence-activated cell sorter purified using different surface markers (CD133, CD90, CD13, cKit) and a functional marker (side population).
The table summarizes the tumor-forming capacity for the indicated number of transplanted cells from the indicated subpopulations of tumor cells. Figure 5 ). The observed changes occurred quickly and in a high percentage of cultured cells, indicating that p53 Ϫ/Ϫ hepatocytes changed differentiation stage. In contrast, p53 ϩ/ϩ hepatocytes did not survive a prolonged culture period and did not exhibit a strong coexpression of those 2 markers until day 14 of culture (Supplementary Figure  6) . In vivo bromodeoxyuridine labeling indicated that loss of p53 impairs the induction/maintenance of hepatocyte quiescence in vivo ( Figure 3A) .
BASIC AND TRANSLATIONAL LIVER
Maintenance of chromosomal stability represents another function of p53 contributing to tumor suppression. [39] [40] [41] [42] There is emerging evidence that loss of p53 checkpoint function can lead to chromosomal instability in stem cells, especially in the context of other genomic insults, such as telomere dysfunction. 5, 41, 43, 44 Here, aCGH analysis revealed that a significantly increased number of freshly isolated progenitor cells (10/28) from nontumorous livers of p53 Ϫ/Ϫ mice carried chromosomal imbalances compared with p53-positive and p21 Ϫ/Ϫ LPCs (2/36; Figure 3B and C, Supplementary Table 2 , and Supplementary Results). Freshly isolated hepatocytes from p53 Ϫ/Ϫ liver represented genomic imbalances similar to p53 Ϫ/Ϫ progenitor cells (3/25; Figure 3B and C, Supplementary Table 2 , and Supplementary Results). An increased rate of chromosomal aberrations was also present in primary colonies derived from single cell-sorted, freshly isolated p53 Ϫ/Ϫ LPCs (10/20; Figure 3B and C) compared with colonies from p53-positive (1/16; Figure 3C ) and p21 Ϫ/Ϫ mice (1/12; Figure 3B and C, Supplementary Table 2 , and Supplementary Results). Together, these data showed that loss of p53 function is associated with increased chromosomal instability of LPCs and hepatocytes.
p53 Deletion Induces Transformation of LPCs and Hepatocytes
Because liver tumors in p53 Ϫ/Ϫ livers showed a mixed differentiation, tumor-forming capacity of bipotent LPCs and hepatocytes were analyzed. Immunocompromised mice were subcutaneously injected with primary cultures derived from bipotent or cholangiocytic progenitor cells or hepatocytes of 2-to 3-month-old mice. Primary cultures from all 3 cell types exhibited robust tumor-forming capacity when isolated from p53 Ϫ/Ϫ liver, whereas cultures from bipotent progenitor cells of wild- Figure 4B ) and hepatocyte cultures exhibited slightly increased tumor-forming capacity ( Figure 4B ). Compared with these results on primary cell cultures, freshly isolated hepatocytes exhibited a strongly reduced tumor-forming capacity (1/40; data not shown). The number of freshly isolated progenitor cells was too low (1000 -2000 cells per mouse) to determine the tumor-forming capacity of freshly isolated, noncultured cells. Although the culture conditions had little effect on chromosomal instability in these cells ( Figure 3B ), it is possible that culture conditions impacted on the tumorigenic potential. Comparing the tumorigenic potential of primary cultures derived from bipotent LPCs of 2-to 3-or 8-to 10-month-old p53 Ϫ/Ϫ mice revealed a significant donor age-dependent increase in the tumorigenic potential, indicating that age-dependent in vivo processes contributed to transformation of these progenitor cells ( Figure 4C ).
The tumors in immunocompromised mice morphologically resembled primary tumors developing in livers of aging p53 Ϫ/Ϫ mice exhibiting a high stromal content and a mixed differentiation with hepatocytic (albumin) and cholangiocytic (K19) differentiation ( Figure 4D and E) . Moreover, aCGH analysis of the tumors showed chromosomal aberrations that partly overlapped with those in primary tumors and in progenitor cells from p53 Ϫ/Ϫ livers ( Figure 4F and Supplementary Figure 7) . Together, these results indicated that liver tumors with bilineal differentiation in p53 Ϫ/Ϫ mice can originate from cholangiocytic or bipotent LPCs as well as from hepatocytes with a changed differentiation status after in vitro culture.
Liver Carcinogenesis in p53-Deficient Mice Associates With Complex Dysregulation of Rb Pathway Genes
Recent studies reported that p53 deletion cooperates with Rb dysfunction in the induction of liver tumor formation. 45 To analyze whether Rb checkpoint function was involved in the development of liver tumors in response to p53 deletion, we analyzed gene expression profiles from spontaneous bilineal liver tumors of p53 Ϫ/Ϫ mice compared with DEN-induced HCCs from p53 ϩ/ϩ mice ( Figure 5 ). Hierarchical clustering analysis revealed that p53 Ϫ/Ϫ tumors clustered separately from DEN-induced tumors ( Figure 5A ). Pathway enrichment analysis of 122 genes involved in the Rb pathway (Supplementary  Table 3 ) resulted in strong separation of p53 Ϫ/Ϫ liver tumors from DEN-induced liver tumors ( Figure 5C ). Of note, the Rb checkpoint genes were significantly more powerful in separating liver tumors from p53 Ϫ/Ϫ versus p53 ϩ/ϩ livers compared with random chosen gene data sets ( Figure 5B ). To investigate an inhibitory or excitatory behavior of the Rb pathway, we performed a literature-based grouping of genes involved in the Rb pathway into indicators of Rb checkpoint activation ("Rb active"; n ϭ 36 of 123) or into indicators of Rb checkpoint inactivation ("Rb inactive"; n ϭ 56 of 123). No statistical difference in proportions of positive versus negative regulated genes of these 2 groups was detected in liver tumors of p53 ϩ/ϩ versus p53 Ϫ/Ϫ mice (Fisher exact test [2-sided] ; P ϭ .3687). These data indicated that differential regulation of Rb checkpoint genes was strongly associated with liver tumor formation in p53 Ϫ/Ϫ versus p53 ϩ/ϩ mice, but this difference in gene regulation was complex and not strictly indicative of Rb checkpoint activation or inactivation.
Discussion
The current study provides the first experimental evidence that p53 deletion as a single genetic lesion induces liver tumors with high penetrance. These data represent the first example for a solid organ where p53 deletion is sufficient to induce tumorigenesis while germline p53 Ϫ/Ϫ mice mainly develop lymphomas and sarco- 
BASIC AND TRANSLATIONAL LIVER
mas. 46 The limited life span of germline p53-deficient mice did not allow studying tumor formation in a solid organ system. Other studies on organ-specific deletion in conditional knockout mice revealed that p53 deletion is not sufficient to induce tumors in brain and intestine. 43, 47 These results indicate that organ-specific differences with regard to the role of p53 in tumor development exist and that loss of p53 per se does not lead to tumor formation in all organs. The current finding that loss of p53 by itself can represent a tumor-initiating lesion in the liver is of particular interest because p53 mutations represent an early lesion in aflatoxin B-induced liver cancer. 16 -18 In contrast, p53 mutations represent a late event in other tumor types, such as intestinal carcinoma. 48 It is conceivable that organ-specific differences in the tumorigenic potential of p53 mutations select for a different order of genetic events and different tumor-initiating events.
This study shows that p53 Ϫ/Ϫ tumors exhibit a mixed differentiation with hepatocytic and cholangiocytic features. Interestingly, there is emerging evidence that loss of p53 function is associated with stem cell-specific gene expression signatures in human HCC. 10, 11 Together with our current mouse model, these findings support a novel concept indicating that loss of p53 function may predispose to the development of dedifferentiated liver tumors exhibiting bilineal differentiation and stem cell features. A possible explanation for these findings could be that p53 deletion leads to tumor formation originating from liver stem/progenitor cells. A variety of previous studies have shown that p53 deletion can increase stem cell self-renewal in various tissues. 7-9 p53 deletion also increased the efficiency to induce pluripotent stem cells (iPS cells). [2] [3] [4] [5] [6] In addition, p53-dependent effects on progenitor cell transformation were reported in mouse models combining p53 deletion with other oncogenic mutations, 13, 14 possibly involving an aberrant enhancement of stem cell self-renewal by increases in symmetric stem cell divisions. 49 The current study suggests that p53 deletion may lead to a prolonged maintenance of the colony-forming capacity of bipotent LPCs during aging.
An alternative explanation for the formation of liver tumors with bilineal differentiation in response to p53 deletion is that loss of p53 function leads to transformation and changes in differentiation status of differentiated liver cells. The study shows that p53 deletion impairs induction of hepatocyte quiescence in vivo. In primary ex vivo cultures, loss of p53 function was required to establish hepatocyte cultures, but these cells quickly developed bilineal differentiation potential. These findings indicate that changed differentiation status and transformation of hepatocytes could contribute to the formation of bilineal liver tumors in response to p53 deletion.
The mechanisms that induce transformation of liver cells in response to p53 deletion remain to be defined. The current study indicates that both LPCs and hepatocytes gain tumorigenic potential in response to p53 deletion. It is possible that (1) an increase in self-renewal of bipotent progenitor cells and (2) a change in differentiation status of hepatocytes contribute to formation of liver cancer with bilineal differentiation in response to p53 deletion. The induction of chromosomal imbalances could play a causal role in cellular transformation in both processes. The current study shows that both hepatocytes and LPC fraction accumulate chromosomal imbalances in response to p53 deletion.
It remains to be delineated which downstream targets of p53 restrict self-renewal of LPCs or alterations in differentiation status of hepatocytes. The current data indicate that the deletion of p21 does not lead to the same increase in self-renewal of bipotent LPCs or the transformation of hepatocytes compared with the deletion of p53. It is possible that other downstream targets of p53 (eg, Puma, 14-3-3 sigma, sestrins) may play a decisive role and that these p53-dependent pathways are differentially regulated in different tissues.
It was reported that the deletion of the p53 checkpoint and Rb checkpoint genes often cosegregate in human HCC, but deletion of the Rb pathway occurs mainly in advanced HCCs. 50, 51 In addition, p53 deletion cooperated with Rb checkpoint deletion in the induction of HCC in mouse models. 45 Our gene expression analysis supports the view that p53 deletion by itself is sufficient to induce liver carcinogenesis. The tumors exhibit a significant dysregulation of Rb checkpoint genes compared with DEN-induced liver tumors in p53 ϩ/ϩ mice. However, these alterations in Rb checkpoint function in p53-deficient liver tumors were complex and not strictly indicative of either activation or inactivation of the Rb checkpoint.
Together, the current study provides the first experimental evidence that p53 deletion leads to formation of liver tumors with bilineal differentiation associated with increases in progenitor cell self-renewal, alterations in hepatocyte differentiation status, and the evolution of genomic imbalances. Tumor development involved complex dysregulation of Rb checkpoint genes and was at least partially independent of p21 checkpoint function.
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Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org, and at doi: 10.1053/j.gastro.2012.02.009. drich) was used according to the manufacturer's instructions with the following modifications. After cell lysis and fragmentation of the genomic DNA, an amplification of the libraries was performed by adding 6 L of 10ϫ amplification master mix, 36 L of nuclease-free water, and 4 L WGA DNA polymerase to 14 L library mix. PCR conditions for amplification were denaturation at 95°C for 3 minutes followed by 25 cycles, with each cycle consisting of a denaturation step at 94°C for 30 seconds and an annealing and extension step at 65°C for 5 minutes. DNA was purified using the Wizard SV Gel and PCR Clean-Up System (Promega, Madison, WI). The quality of the amplification was evaluated using a multiplex PCR approach as previously described. 5 
Bromodeoxyuridine Treatment of Mice
Mice were continuously labeled with bromodeoxyuridine (BrdU; Sigma-Aldrich) in the drinking water (0.8 mg/mL) for 7 to 28 days. Drinking water was replaced every 24 hours.
BrdU Staining of Hepatocytes
Freshly purified hepatocytes from BrdU-labeled mice were fixed with 70% ethanol and stained for BrdU incorporation with an anti-BrdU fluorescein isothiocyanate-labeled antibody (BD Biosciences) according to the manufacturer's protocol. The cells were analyzed on a BD FACS LSRII flow cytometer.
BrdU Staining of LPCs
Freshly isolated adult LPCs from BrdU-labeled mice were sorted on a poly-L-lysin-coated glass slide. The cells were fixed with 70% ethanol. DNA was denatured with 4N HCl/0.5% Tween 20 for 15 minutes. Afterward, the cells were stained with an anti-BrdU Alexa Fluor 488 -labeled antibody (Invitrogen, Carlsbad, CA). The cells were analyzed on a Leica fluorescence microscope.
Terminal Deoxynucleotidyl Transferase-Mediated Deoxyuridine Triphosphate Nick-End Labeling (TUNEL) Staining of Cultured Hepatocytes
Cells were stained using the In Situ Cell Death Detection Kit, Fluorescein (Roche Applied Science, Indianapolis, IN) according to the manufacturer's protocol.
RNA Isolation
Total RNA was isolated from shock frozen tissue by using RNAzolB (WAK Chemie, Steinbach, Germany) according to the manufacturer's protocol. For microarray analysis, total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. The quality of the RNA was analyzed with the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Samples with a RIN factor Ͼ5.9 were used for further analysis.
Quantitative Real-Time PCR
Quantitative real-time PCR was performed with an ABI 7300 Real-Time PCR System (Applied Biosystems) in triplicate from at least 4 biological samples. The Superscript III Kit (Invitrogen) was used for complementary DNA synthesis. TaqMan assays for CD133 and CD90 (Applied Biosystems) were performed in a volume of 25 L.
Rb Pathway Gene List
A set of genes related to the Rb pathway (upstream genes, interaction partners, downstream targets) was established for comparison of gene expression data from p53 Ϫ/Ϫ liver tumors and p53 ϩ/ϩ DEN-induced liver tumors. Genes were selected from published data using the PubMed database. A detailed list of selected genes is specified in Supplementary Table 3 . The corresponding references are listed in the Supplementary References for the Rb pathway gene list. To investigate an inhibitory or excitatory behavior of the Rb pathway, we performed a literature-based grouping of the Rb-related genes into indicators for an active Rb pathway ("Rb-active"; n ϭ 36 of 123) or into indicators for an inactive Rb pathway ("Rb-inactive"; n ϭ 56 of 123). Due to conflicting literature reports, 31 genes could not be assigned to either group. Detailed lists for these 2 groups are available as Supplementary Tables 4 and 5 .
Analysis of Gene Expression Data
Expression data were extracted using the Feature Extraction software (Agilent Technologies). Preprocessing of expression data was performed according to Agilent's standard workflow. Using 5 quality flags (gIsPosAndSignif, gIsFeatNonUnifOL, gIsWellAboveBG, gIsSaturated, and gIsFeatPopnOL) from the Feature Extraction software output, probes were labeled as detected, not detected, or compromised. Gene expression levels were background corrected, and signals for duplicated probes were summarized by geometric mean of noncompromised probes. After log 2 transformation, a percentile shift normalization at the 75% level and a baseline shift to the median baseline of all probes was performed. All computations were performed using the R statistical software framework (http://www.R-project.org).
Hierarchical clustering with Euclidean distance and average linkage was performed using all available probe sets and is shown as a dendrogram. Expression pattern of Rb pathway genes (Supplementary Table 3 ) is shown as a heat map for DEN and p53 knockout samples. Gene set enrichment analysis was performed as described as follows. 6 The amount of differential expression of the individual genes (gene level statistics) was measured by Spearman correlation coefficient. The bias from using multiple probe sets targeting the same genes was adjusted by summarizing the different probe sets. The mean absolute value of single gene statistics was used as the gene set statistic and was compared with the null hypothesis of no association of genes to the phenotype. Computerintensive Monte Carlo simulation (gene sampling) was performed to assess the significance of the observed gene set statistic. Results from simulations are shown as a histogram, including the result for the Rb pathway gene set.
Supplementary Results
aCGH Analysis of Primary Liver Tumors in
Conditional p53 ؊/؊ Mice and in DENTreated Mice p53-deleted liver tumors showed a distinct pattern of chromosomal aberrations; the chromosomes 9, 12, and 15 were mainly affected, whereas DEN-induced liver tumors showed only a few aberrations with a random pattern, and a dominance was only recognized in a partial gain of chromosome 12.
aCGH Analysis of LPCs and Hepatocytes
